Erlotinib vs Nivolumab

Erlotinib vs Nivolumab: Overview

This comparison examines the pharmacological differences between Erlotinib and Nivolumab.

Mechanism of Action

Erlotinib: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Erlotinib — 36 hours; Nivolumab — 27 days.

Chemical Properties

Molecular Formula: Erlotinib — C22H23N3O4.

Molecular Weight: Erlotinib — 393.4380 g/mol.

Type: Erlotinib — Small molecule; Nivolumab — Antibody.